Li Lu, Wang Xiaojuan, Wang Rongrong, Hu Yunzhen, Jiang Saiping, Lu Xiaoyang
Department of Pharmacy, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, People's Republic of China.
Drug Des Devel Ther. 2020 Jul 28;14:3001-3013. doi: 10.2147/DDDT.S259058. eCollection 2020.
Coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is now a global outbreak of disease. The antiviral treatment acts as one of the most important means of SARS-CoV-2 infection. Alteration of physiological characteristics in special populations may lead to the change in drug pharmacokinetics, which may result in treatment failure or increased adverse drug reactions. Some potential drugs have shown antiviral effects on SARS-CoV-2 infections, such as chloroquine, hydroxychloroquine, favipiravir, lopinavir/ritonavir, arbidol, interferon alpha, and remedsivir. Here, we reviewed the literature on clinical effects in COVID-19 patients of these antiviral agents and provided the potential antiviral agent options for pregnant women, elderly patients, liver or renal dysfunction patients, and severe or critically ill patients receiving renal replacement therapy or ECMO after SARS-CoV-2 infection.
由严重急性呼吸综合征冠状病毒2（SARS-CoV-2）引起的2019冠状病毒病（COVID-19）目前已在全球爆发。抗病毒治疗是治疗SARS-CoV-2感染最重要的手段之一。特殊人群生理特征的改变可能导致药物药代动力学的变化，进而可能导致治疗失败或药物不良反应增加。一些潜在药物已显示出对SARS-CoV-2感染的抗病毒作用，如氯喹、羟氯喹、法匹拉韦、洛匹那韦/利托那韦、阿比多尔、干扰素α和瑞德西韦。在此，我们回顾了这些抗病毒药物在COVID-19患者中的临床疗效相关文献，并为SARS-CoV-2感染后的孕妇、老年患者、肝肾功能不全患者以及接受肾脏替代治疗或体外膜肺氧合（ECMO）的重症或危重症患者提供了潜在的抗病毒药物选择。
